- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00437957
Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases
Phase I Trial Of Temozolomide Combined With The Histone Deacetylase Inhibitor Valproic Acid (VPA) And Whole Brain Radiation Therapy (WBR) For Brain Metastases From Solid Tumors In Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At the start of the study, patients will be informed which dose level they will be treated with. On day 1, patients will have a physical exam and several blood draws including draws to measure the level of valproic acid in their body. Patients will start your whole brain radiation and also at the same time start the valproic acid and temozolomide pills. Patients will be asked to take the valproic acid pills every 12 hours and the temozolomide pills once daily. Patients will not need to come to the center for that but will need to come to the center to receive you whole brain radiation for 3 weeks (on weekdays, excluding holidays). Radiation therapy will not be administered on weekends but patients will still take their pills for the whole 3 weeks from starting the radiation.
Patients will have to come back for a study visit weekly for the 6 months. Two more visits are also required: approximately 6 weeks and 10 weeks from starting the treatment. Patients will be asked about any old or new symptoms to determine if adjustment in the pill dose is required.
Every study visit except the last one will include blood draws. These will evaluate blood counts, blood chemistry and also measure the level of valproic acid in your body. The Mini Mental Status examination described above will be repeated in every visit.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center & Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have cytologically/histologically documented solid tumor malignancies
- Age > 18 years old
- Patients must be candidates to receive WBR for unresectable brain metastases
- Patients must have ECOG performance status 0-2
- Patients must be able to give informed consent and able to follow guidelines given in the study
- Neurologic Function Status 0,1, or 2
- The patient has no major impairment of hematological function, as defined by the following laboratory parameters: WBC >3.0x10^9/L; ANC > 1.5 x 10^9/L; Hgb >9.0g/dL; PLT >100x10^9/L. Red blood cell transfusions and repeat evaluations for study entry are allowed
- Patients must have adequate renal and normal hepatic function (creatinine < 1.5 x upper limit of normal (ULN), bilirubin and SGOT (AST), SGPT (ALT) within 1.5 x the upper institutional normal limits) obtained within 4 weeks prior to registration.
- All patients of reproductive potential must use an effective method of contraception during the study and six months following termination of treatment. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to female patients who are older than 50 years and have not had a menstrual cycle in more than one year).
- Women of childbearing age must have a negative pregnancy test
- Patients must have 10 mm or greater brain lesion on MRI scan performed within 4 weeks of enrollment
Exclusion Criteria:
- Prior whole brain radiation
- More than 1 active malignancy which may potentially cause brain metastasis
- Patients on phenytoin, carbamazepine, phenobarbital, felbamate, meropenem, rifampin (Levetiracetam will be permitted)
- Patients with active or any history of seizure disorders
- Patients with uncontrolled nausea and vomiting
- Chemotherapy, radiotherapy, or hormonal therapy within 2 weeks prior to entering the study or have not recovered from prior treatment-related toxicities (grade 2 or less)
- Patients receiving any other investigational agents
- Evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study entry.
- Leptomeningeal disease or hydrocephalous on MRI scan performed within 4 weeks of enrollment
- Pregnant and breast feeding women are excluded from the study because effects on the fetus are unknown and there may be a risk of increased fetal wastage.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Temazolomide, Valproic Acid and Radiation
Temazolomide, Valproic Acid and Whole Brain Radiation Therapy
|
75 Mg/m2/day for all Cohorts
Other Names:
Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
Other Names:
Concurrently with Temozolomide and VPA
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability of temozolomide in combination with VPA and Whole-Brain Radiation
Time Frame: approximately 74 days per patient
|
approximately 74 days per patient
|
Determination of the MTD of VPA in combination with temozolomide and Whole-Brain Radiation
Time Frame: approximately 74 days per patient
|
approximately 74 days per patient
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Response rate
Time Frame: approximately 74 days per patient
|
approximately 74 days per patient
|
Pharmacokinetics
Time Frame: approximately 74 days per patient
|
approximately 74 days per patient
|
Histone acetylation
Time Frame: approximately 74 days per patient
|
approximately 74 days per patient
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sajeel Chowdhary, MD, H. Lee Moffitt Cancer Center and Research Institute
- Principal Investigator: Jade Homsi, MD, H. Lee Moffitt Cancer Center and Research Institute
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Neoplasms by Site
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neoplasm Metastasis
- Brain Neoplasms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Tranquilizing Agents
- Psychotropic Drugs
- GABA Agents
- Anticonvulsants
- Antimanic Agents
- Temozolomide
- Valproic Acid
Other Study ID Numbers
- MCC-14886
- 105003A (Other Identifier: USF IRB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastases
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingRecurrent Brain Metastases | Progressive Brain MetastasesUnited States
-
AC Camargo Cancer CenterCarl Zeiss Meditec AGTerminatedBrain Metastases, Adult | Central Nervous System MetastasesBrazil
-
Rigshospitalet, DenmarkRecruitingCancer | Brain Metastases, AdultDenmark
-
Susanne RogersUniversity of Basel; Technical University of MunichRecruitingBrain Metastases, AdultSwitzerland
-
British Columbia Cancer AgencyVarian Medical SystemsRecruitingBrain Metastases, AdultCanada
-
IRCCS San RaffaeleRecruitingBrain Metastases, AdultItaly
-
AHS Cancer Control AlbertaRecruitingBrain Metastases, AdultCanada
-
University Health Network, TorontoRecruiting
-
Centre Francois BaclesseGroupement Interrégional de Recherche Clinique et d'Innovation; ANOCEF/IGCNORecruitingHemorrhagic Brain MetastasesFrance
-
Duke UniversityVarian Medical SystemsCompleted
Clinical Trials on Temozolomide
-
Guangzhou Medical UniversityUnknownSmall Cell Lung Cancer | Metastatic CarcinomaChina
-
University of SouthamptonBristol-Myers SquibbRecruitingCancer of Esophagus | Adenocarcinoma - GEJUnited Kingdom
-
Novartis PharmaceuticalsCompletedGlioblastomaAustralia, Spain, Canada, United States
-
Activartis BiotechCompleted
-
Bradmer Pharmaceuticals Inc.Terminated
-
Peking Union Medical College HospitalBeijing Tiantan Hospital; Tianjin Medical University General HospitalUnknownMalignant GliomasChina
-
Yunpeng LiuUnknownExtensive Stage Small Cell Lung CancerChina
-
Haukeland University HospitalUniversity of Oslo; Oslo University Hospital; University Hospital of North Norway and other collaboratorsRecruiting
-
Merck Sharp & Dohme LLCTerminatedBreast Neoplasm | Brain Neoplasm | Second Neoplasm
-
Merck Sharp & Dohme LLCTerminatedCarcinoma, Non-Small-Cell Lung | Brain Neoplasms | Metastases, Neoplasm